Quantum Cyber (formerly Mainz Biomed) is a pre-revenue development-stage diagnostics company undergoing a significant strategic pivot. Its primary focus is developing a blood-based pancreatic cancer detection test built around a licensed portfolio of mRNA biomarkers and a proprietary AI algorithm acquired from Liquid Biosciences in early 2025. In early lab studies, this biomarker/algorithm combination showed 95% sensitivity and 98% specificity. The company paid a $1.2M upfront license fee and holds an exclusive option to acquire full global rights. The company is also developing PancAlert, an earlier-stage stool-based pancreatic cancer test. Neither product has completed clinical validation studies, and neither is commercialized. The company's prior operating business, ColoAlert, was a stool-based colorectal cancer screening test sold to labs across Europe. ColoAlert was wound down in early 2026 due to insufficient funding, and its IP was sold for roughly $349K. The company has also stated an intention to expand into post-quantum cybersecurity, though no products, customers, or revenue exist in that area. Quantum Cyber has no revenue-generating products and is reliant on a $6M private placement from investor David Lazar as its primary source of operating capital. If fully converted, Lazar's preferred shares would give him over 95% of outstanding ordinary shares. The company employs roughly 13 people and faces a Nasdaq minimum bid price compliance deadline in September 2026.